Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial
- 31 December 2009
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 10 (12), 1145-1151
- https://doi.org/10.1016/s1470-2045(09)70307-9
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Adjuvant Chemotherapy in Older Women with Early-Stage Breast CancerNew England Journal of Medicine, 2009
- Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialThe Lancet, 2009
- Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trialAnnals of Oncology, 2009
- Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2008
- Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized TrialsJournal of Clinical Oncology, 2008
- Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective studyZeitschrift für Krebsforschung und Klinische Onkologie, 2007
- Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 TrialJournal of Clinical Oncology, 2006
- Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast CancerJournal of Clinical Oncology, 2006
- Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology, 2006
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005